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Abstract
HIV-1 protease represents an appealing system for directed enzyme re-design, since it has
various different endogenous targets, a relatively simple structure and it is well studied.
Recently Chaudhury and Gray (Structure (2009) 17: 1636 – 1648) published a compu-
tational algorithm to discern the specificity determining residues of HIV-1 protease. In
this paper we present two computational tools aimed at re-designing HIV-1 protease,
derived from the algorithm of Chaudhuri and Gray. First, we present an energy-only
based methodology to discriminate cleavable and non cleavable peptides for HIV-1 pro-
teases, both wild type and mutant. Secondly, we show an algorithm we developed to
predict mutant HIV-1 proteases capable of cleaving a new target substrate peptide, dif-
ferent from the natural targets of HIV-1 protease. The obtained in silico mutant enzymes
were analyzed in terms of cleavability and specificity towards the target peptide using
the energy-only methodology. We found two mutant proteases as best candidates for
specificity and cleavability towards the target sequence.
List of Abbreviations
PR HIV-1 protease.
WT-PR Wild type HIV-1 protease.
mutant PR Mutant HIV-1 protease.
Pr3 set Set of mutant proteases derived from Pr3, a mutant protease developed by Alvizo
et al. These were heterodimer proteases.
DR set Set of mutant proteases derived as a subset of HIV-1 proteases that have been
found to be drug resistant. These were homodimer proteases.
2Introduction
Proteases represent a class of enzymes ubiquitous in all living organisms, with multiple
applications in industry and biotechnology research [1–3]. There is thus interest in de-
signing new proteases capable of cleaving specific peptide sequences [4]. HIV-1 protease
(PR) represents an attractive starting structure for directed enzyme re-design, since it is
known to cleave a variety of sequences. PR is the enzyme responsible for processing the
gag – pol fusion polyproteins of the HIV virus [5]. PR is an aspartic protease [6–8] and is a
homodimer where each chain is composed of 99 residues. Wild type PR (WT-PR) is very
specific for the endogenous cleavage sequences of the polyprotein (endogenous substrate
peptides, Table 1S), even if the source of this specificity is still not completely clear. A
series of other non-endogenous peptides have also been found to be cleaved by PR. The
latest hypothesis on the origin of this specificity, called dynamic substrate envelope [9,10],
states that peptides fitting into the protease cavity through a certain number of hydrogen
bonds will be bound and possibly cleaved nearly regardless of their amino acid composi-
tion. In fact, there is no clear trend in amino acid sequence (e.g. a negatively charged
amino acid in position P1 or a hydrophobic one in position P2’). This suggests that with
few mutations PR could be made to cleave other target peptide sequences in a specific
manner.
Many computational studies on PR, both wild type (WT) and drug resistant mutant
enzymes, are aimed at elucidating the affinity of the enzymes towards endogenous sub-
strates and inhibitors to be used as drug candidates [11–14]. Recently Chaudhury and
Gray [15] published a computational algorithm specifically tailored for PR and aimed at
the identification of the specificity determining residues. The algorithm is based on Py-
Rosetta [16], a python script-based interface to Rosetta [17]. Thanks to the algorithm the
authors were able to predict accurate protease – substrate complex structures (within 1.1
A˚ rms of the corresponding crystal structure) and introduced an energetic discrimination
of cleavable peptides. More recently Alvizo et al. [18] employed computational methods to
re-engineer a mutant PR (Pr3) more specific for one of the endogenous peptide sequences
over two others.
The first aim of this study is to develop an energy-only based methodology to discern
cleavable and non cleavable peptides for PRs, WT and mutant. This methodology is based
on the qualitative evaluation of PR:peptide complexes binding energies and is derived from
the algorithm developed by Chaudhury and Gray. The second aim is to search and define
an algorithm to predict mutant PRs capable of cleaving a specific target peptide sequence
different from any endogenous substrate. We use our cleavability discerning methodology
on the suggested mutant proteases, in order to define the best guess in terms of specificity
towards the peptide sequence. In other words, the sought after mutant structure has to
show better and worse binding towards the target and endogenous peptides, respectively,
than WT-PR. To the best of our knowledge ours is the first study aimed at predicting a
mutant PR capable of cleaving specifically a non endogenous peptide sequence.
3The paper is organized as follows: first, we present our computed binding energies for
known cleavable and non-cleavable peptides bound to WT-PR, selected peptides bound
to a set of single, double and triple mutants (Pr3 set) derived from Pr3 as developed by
Alvizo et al., and a set of known mutant PRs and peptide derived from drug resistance
(DR set) studies [19–21]. Secondly, we present two different versions of our algorithm to
determine mutant PRs that will cleave the sequence HFLSF*MAIP, where the * symbol
indicates the desired cleaving site. A discussion about the best strategy to suggest mutant
enzymes follows. The conclusions summarize the main findings of the paper, followed by
a detailed description of the employed computational methods.
Results and Discussion
Development of a Cleavability Test
In general, the activity of an enzyme towards two similar substrates is regulated by (i) the
strength of the enzyme-substrate binding and (ii) the efficiency of the enzymatic reaction.
The two processes are regulated by two constants, usually indicated as km and kcat,
respectively. The overall enzymatic efficiency is given by the ratio of these two constants.
The dynamic substrate envelope hypothesis [10] suggests that if a peptide is bound to PR
it will be cleaved. Thus, we decided to evaluate the binding energy of different peptides
to PR, which can be correlated to km. We then compared the computed binding energies
to PR of known cleavable and non cleavable peptides, to be correlated to corresponding
ranges of binding energies. By so doing we disregarded kcat, that is we did not consider
possible effects from the enzymatic reaction.
The cleavability test was developed by considering binding energies of WT-PR with
its endogenous and known cleavable substrates and known non-cleavable peptides. Af-
terwards we investigated the reliability of the test with mutant PRs (the Pr3 set) when
binding PR endogenous substrates. Finally, we assessed the test on mutant PRs (the DR
set) when binding mutant substrates.
The complete methodology for evaluating binding energies is described in the compu-
tational methods section. In brief, it is composed by a structure optimization algorithm,
followed by an energetic re-evaluation of the obtained structures. In the following para-
graphs we evaluate our methodology in terms of binding energies versus cleavability for:
(1) WT-PR and its endogenous substrates and known cleavable and non-cleavable pep-
tides, (2) the Pr3 set of mutant PRs and endogenous substrates and (3) the DR set with
wild type and mutated endogenous peptides. Binding energies were computed also for
WT-PR and all mutant PRs in complex with octa-alanine (poly-Ala) and octa-arginine
(poly-Arg) peptides to test for aspecific binding.
(1) Table 1 reports the computed binding energies of the set of known cleavable en-
dogenous peptides of WT-PR. The sequence of the tested endogenous cleavable peptides
is reported in Table 1S. Alongside the endogenous peptides, a set of 59 known cleavable
4peptides was also tested. The sequence of the 59 tested non-endogenous cleavable peptides
was obtained as previously described [15, 22–26]. Table 5S reports the computed bind-
ing energies to WT-PR and Table 2S the sequences of these non-endogenous peptides.
Table 6S reports the computed binding energies of a set of peptides supposedly non-
cleavable by WT-PR. The sequence of the 43 tested non-cleavable peptides was obtained
as previously described [15, 26, 27] and is reported in Table 3S.
We performed a Mann-Whitney’s U test [28] to compare the computed binding en-
ergies, and found a significant difference between the cleavable and non-cleavable sets (p
≈ 10−7), as reported in Table 2. Thus, we deemed the binding energy criterion sufficient
to achieve discrimination. We further analyzed the computed binding energies through an
ROC plot [29] relative to different cutoff values, so as to differentiate between cleavable and
non-clevable peptides. The plot is reported in Figure 1, and the relative data in Table 11S.
The computed area under ROC [30] is 0.79 and 0.80 for FMO and RosettaDock energies,
respectively, being the values of 0.50 and 1.00 typical correspondingly of a useless and a
perfect test. Through the ROC plot, we found the best cutoff values discerning cleavable
and non-cleavable peptides as those closest to (0, 1), which represents the theoretical
perfect test. We found that cutoff values of -25 kcal/mol and -3 kT are best at dis-
cerning FMO and RosettaDock computed binding energies, respectively. Both FMO and
RosettaDock perform well in computing binding energies capable of discerning cleavable
and non-cleavable peptides. However, Figure 1S shows that there is no apparent correla-
tion between FMO and RosettaDock computed binding energies. Thus, we repeated the
Mann-Whitney’s U test and ROC analysis excluding the set of non-endogenous known
cleavable peptides binding energies. The rationale behind this analysis is that we expect
WT-PR to bind the endogenous peptides with higher affinity, as opposed to the broader
range of the complete cleavable set, characterized only by cleavability and not specificity.
Consequently, we assume that the endogenous peptides set have better binding energies,
than the complete set of cleavable peptides. The Mann-Whitney’s U test (Table 2) shows
that the RosettaDock based binding energies are in this case two orders of magnitude
worse than FMO at discerning cleavable and non-cleavable peptides. The relative ROC
plot (Figure 2S) shows as well that the FMO data performs better than RosettaDock, in
terms of more strict best cutoff value and larger area under the ROC. Thus, we concluded
that FMO computed binding energies are better than RosettaDock ones since are capable
of discerning expected effects, such as the usage of a better performing subset of peptides.
In the rest of this paper we will discuss only binding energies computed through FMO
energy re-evaluation.
From Table 1 it is expected that WT-PR exhibits qualitatively different binding to the
poly-protein substrates, given their computed binding energies ranging from -41 for the
binding of p6pol-PR to -72 kcal/mol for p2-NC, with an average value of -60 kcal/mol.
However, available experimental Km values [22] do not show any trend similar to the
computed data. Still, one has to remember that these computed binding energies should
be considered only qualitatively and only compared to others obtained in the same man-
5ner. See the Computational Methods section for further details. Furthermore, the span
of both computed energies for which experimental data are available (20 kcal/mol) and
the Km values (2 orders of magnitude) is too small to allow a clear trend. The computed
binding energies for the set of cleavable non-endogenous peptides span a wide range of
values, from -2 to -86 kcal/mol, with average -40 kcal/mol. These peptides not being the
natural target of WT-PR may account for this large span. The average computed binding
energy for all cleavable peptides is -43 kcal/mol. The computed binding energies for the
non-cleavable set of peptides (Table 6S) span an even wider range of values than those of
the cleavable ones. Some PR – peptides complexes show positive energies. The majority
(56%) of the computed binding energies are in the range -35 – 0 kcal/mol. However, a
few peptides show a binding energy to WT-PR similar to those of the cleavable peptides.
(2) Recently Alvizo et al. [18] suggested through computational means a triple mutant
(Pr3) with increased binding capability towards the endogenous RTp51-RTp66 cleavage
sequence peptide compared to that towards other two cleavage sequences CA-p2 and p2-
NC. The efficiency of Pr3 in cleaving preferentially RTp51-RTp66 was later experimentally
verified. Pr3 was made by tethering a mutated chain of protease (A28S, D30F, G48R)
to a wild type one. For comparison with our predicted mutant PRs, Table 3 reports our
computed binding energies for the Pr3 three-fold mutant, as well for simpler one- and two-
fold mutant PRs derived from Pr3 (Pr3 set), as compared to WT. Note, however, that
experimental data are available only for the three-fold mutant PR. In our calculations, Pr3
set carried mutations only on chain A, while still being formed by two separate chains. We
expected to find that Pr3 computed binding would be stronger towards RTp51-RTp66,
while weaker towards CA-p2 and p2-NC, compared to WT-PR. The computed binding
energies of the Pr3 set show that the mutant enzymes often have higher affinity for the
desired RTp51-RTp66 peptide compared to CA-p2 and p2-NC. Most notably the double
mutant A28S/G48R has a stronger computed binding energy towards the target peptide
than WT-PR, while lower for the other two endogenous substrates. The binding energy
test indicates that A28S/G48R (for which there is no experimental data available) would
have been a more successful mutation than Pr3. Nevertheless, the possibility of using the
binding energy test with mutant PRs was found viable.
(3) Finally we decided to apply the binding energy test to series of mutant PRs binding
mutant endogenous substrates. Thus, we evaluated the binding energies of drug resistant
HIV-1 proteases towards wild type and mutant substrate peptides. It has been found
that mutations of the cleavage sites are correlated to mutations of the protease, often
leading to drug resistance. We analyzed the K436R and A431V mutations of the NC-p1
Gag substrate peptide cleavage sequence in relation to a series of single mutations and
one double mutation of HIV-1 protease (DR set). It has been reported [19] that a K436R
mutation increases resistance to protease inhibitor drugs when combined with I50V, I84V
and I84V/L90M PR mutations, while the A431V mutation results in a more efficient
PR regardless of other mutations. We expected that the more efficient mutant PR –
mutant peptide combinations were also characterized by stronger
6reports the results of our binding energy test for the DR set. Our methodology indicates
cleavability for all combinations of mutant PRs and mutated NC-p1 substrate peptides.
While there are some fluctuations in the binding energies, no clear pattern arises that can
be related to the experimental findings. Possibly, the increased efficiency of drug resistant
mutant proteases towards mutated peptides is related to kcat. As previously stated, the
effects of this constant are not considered by the present approach. Nevertheless, the
binding energy test was found suitable also for combinations of mutant PRs with any
peptide.
Prediction and Analysis of Mutant PRs
The second aim of this study was to develop a computational methodology for the design of
a mutant PR. The sought after enzyme had to be capable of cleaving a new target substrate
different from the endogenous ones. The obtained mutant PR should also be specific for
the target peptide sequence compared to the endogenous peptides. The chosen sequence
for the target peptide was HLSF*MAIP, where the * symbol indicates the desired cleaving
site. The sequence was extracted from that of κ-casein. Once candidate mutant PRs were
obtained, we employed the binding energy test to asses the enzymes cleaving capabilities.
The possibility of an increase in cleaving capability towards the target substrate was
asserted by differences in binding energy between WT-PR and mutant PRs. We evaluated
the binding energies of mutant PRs in complex with the TF-PR peptide, used as a starting
template (see the Computational Methods section), and the CA-p2 and p2-NC peptides
(for selected mutant PRs) in order to test the specificity of our mutant PRs.
The mutant-generating algorithm is described in details in the Computational Methods
section. Two main strategies (Strategy1 and Strategy2) were employed for generating
mutant PRs. In Strategy1, the side chains of only the 6 residues previously indicated as
specificity determining [15] were allowed to change. The analysis of the binding energies
of the mutant PRs generated by Strategy1 found the enzymes insufficient to perform the
desired scope. This prompted us to further develop the algorithm. In Strategy2, the side
chains of 26 residues were allowed to change. See the Computational Methods section
for further details on the residues choice. The analysis of the binding energies of these
mutant PRs found some of the predicted enzymes to be adequate to cleave the desired
target sequence.
Tables 7S and 8S in the Supporting material reports the Strategy1 mutant PRs (M1
–M16) and their computed binding energies towards the targetpeptide and TF-PR, CA-
p2 and p2-NC endogenous peptides. Among these mutant PRs, M5 shows the strongest
binding energy towards the target peptide. However it has to be noted that the computed
binding energy of M5 towards the TF-PR peptide (used as a starting template for all
mutant enzymes) is also stronger with respect to WT. Possibly M5 is simply a better
generic binder. To verify this hypothesis we tested M5 as a binder also for other two
endogenous peptide sequences, CA-p2 and p2-NC. Compared to WT-PR,M5 has weaker
7binding energy for the former peptide, but equal for the latter. In conclusion, M5 is
not predicted to be more specific for the target sequence than for the endogenous pep-
tides. Moreover, M5 was not directly predicted through Strategy1, but as a homodimeric
derivative ofM2, which shows only a small improvement in binding of the target peptide.
All other mutant PRs suggested by Strategy1, M1 – M4 and M6 – M16, were found
having a weak binding energy towards the target peptide, with some of them showing
prominently positive binding energies. It can be concluded that Strategy1 is unsatisfac-
tory at predicting a mutant PR with an increased and specific affinity towards the target
peptide. This is possibly due to the fact that allowing only six residues to change is too
strict a condition to achieve a suitable mutant PR.
Thus, we decided to further improve the mutation algorithm by including more residues
among those that can be changed. The six generations of mutant PRs computed through
our Strategy2 mutant algorithm are presented in Table 5. We refer to them as generations
since at each macro step of the algorithm the lowest in energy (as computed with the
standard RosettaDock energy function) structure was used as starting point for the next
step. The sixth generation (M23) did not produce any new change with respect to the
fifth (M22), and the algorithm was consequently terminated. For each generation the
structure with the lowest absolute energy was further optimized. After generation 1 two
mutant structures were chosen (M17 and M18) since they are very close in energy (as
evaluated with the RosettaDock energy function, data not shown) but relatively different
as mutation sites. In addition, an extra mutant PR (M24) was generated as homodimer
ofM22. The computed binding energies of the Strategy2 mutant PRs (M17 – M24) are
shown in Table 6. All Strategy2 mutant PRs show a binding energy towards the target
sequence two to four fold stronger than WT-PR, with M17 displaying the strongest
binding energy. However, as for M5, binding energies towards the template peptide TF-
PR as well as CA-p2 and p2-NC are also stronger than WT. Possibly M17 is also a good
but generic binder. Through the subsequent generations of mutant proteases, at lastM22
shows a binding energy towards the target peptide more than three fold stronger than
WT, while the computed binding energy towards the natural endogenous substrates is
weaker than WT. Similar results were obtained for its homodimer M24. M22 and M24
show binding energies below the cutoff value of -25 kcal/mol, and thus represent the best
candidates to be further studied experimentally.
We compared the structures of WT-PR andM24 as optimized while binding the target
peptide. Figure 2 reports the superimposed backbones of the two enzymes after structure
alignment. The two computed structures are quite coincident. Hence, it is expected that
M24 should retain the main structural features of the wild type enzyme. We also tried to
analyze the choice of changed residues. Figure 3 shows that the residues that were changed
from WT-PR to M24 are disposed all around the bound peptide. Figures 3S – 14S given
as supporting material compare each residue that differs between WT-PR andM24, while
bound to the target peptide. Although it is evident that the A28S substitution on chain
A introduces a hydrogen bond between the residue and the side chain of the serine in the
8peptide (Figure 3S), the other substitutions are less easily rationalized. On going study
aims at elucidating the role of the other residues substitutions.
It is interesting to note that Strategy2 mutated only 7 out of the 26 residues that were
set as mutable in the method. It is also worth noting that of the 7 residues (A28, D30,
K45, I50, P81, V82, I84) suggested by Strategy2 in the various mutant generations, A28,
K45, P81 are not included in the set of major mutations site of HIV-1 protease responsible
for drug resistance [31], that is: D30, V32, M46, I47, G48, I50, I54, Q58, T74, L76 V82,
N83, I84, N88, L90. A28, K45, and P81 together with I50 are also not included in the
specificity determining residues set [15]. However, A28 was located by Alvizo et al. for
the Pr3 mutant [18]. We envision Strategy2 also as a tool to locate those residues most
involved in binding a given substrate peptide.
From the analysis of the different PRs, mutant and wild type, and their binding ener-
gies, it is worth to note that WT-PR has a certain affinity with the octa-arginine peptide.
Its computed binding energy is at the limit to consider the octa-arginine peptide as cleav-
able by WT-PR. Possibly this relatively strong binding is given by very few interactions.
Accordingly, the single D30F change on chain A, that is changing one negatively charged
residue into an aromatic hydrophobic one, is able to drop the computed binding energy to
0, as shown in Table 4. The currently going analysis of the residue by residue interactions
for the modified side chains will give further information also on this aspect of the binding
of PR.
Finally, it is interesting to note that the algorithm is not always preserving amino acid
side chain changes through the generations. For example, I84V on chain A is introduced
in M18 and kept in M19, M20 and M21, but later reverted. Possibly, an isoleucin in
position 84 is energetically more favorable, given the other side chain changes.
Conclusions
In the first part of this study we developed a methodology to test the cleavability of a
peptide by HIV-1 protease (Tables 1 and 6S), solely based on the binding energy between
the enzyme and the substrate. The methodology can also be applied to mutant PRs, Ta-
ble 3. The technique is based on a PyRosetta algorithm generating, iteratively, optimized
structures, coupled with an energy re-evaluation at a higher level of theory (FMO/PCM
MP2/6-31G(d)).
In the second part of this study, the optimization algorithm was extended to permit
the stochastic change of the side chain of selected residues, in order to better bind a given
target peptide sequence. The selected target peptide was required to be different from the
endogenous peptides. The desired outcome was a mutant PR with stronger and weaker
predicted binding energy for the target and endogenous peptides, respectively, compared
to WT-PR. The mutant PRs M22 and M24 generated through Strategy2 exhibit such
desired characteristics (Table 6). We analyzed the backbone structure of WT-PR and
9M24 and found no major differences, thus indicating thatM24 should retain the general
structure features of wild type HIV-1 protease. Strategy2 algorithm is able to predict
mutations outside the usual set of residues involved in drug resistance, possibly giving an
ulterior insight into the binding process of HIV-1 protease.
Ongoing experimental studies will show if and how well M22 and/or M24 bind and
cleave the target sequence. Our current experimental and computational studies are also
aimed at analyzing M24 mutations, residue by residue and in combination, and their
possible role in binding the target sequence. It is our hope that the experimental tests
will provide enough information to be used to further improve the mutant generating
algorithm. If the combination of computational algorithm and experimental verification
is successful it will maybe permit the design of mutant PRs specific for any given substrate
peptide.
Computational Methods
In general, the activity of an enzyme towards two similar substrates is regulated by (i)
how good the enzyme-substrate binding is and (ii) how efficient the enzymatic reaction
is. Following the dynamic substrate envelope hypothesis [9, 10], we assume a correlation
between the binding of different peptides to PR and cleavability of the former. Thus we
compute qualitative binding energies, on the premise that lower binding energy equals
better cleavability.
Binding Energies
PyRosetta Algorithm
The structure of wild type (WT) HIV-1 protease in complex with different octa-peptides
was optimized using PyRosetta 1.1, [16] a python script-based interface to Rosetta, [17]
and the algorithm depicted in Figure 4. The algorithm is based on the flexible peptide-
docking algorithm used by Chaudhury and Gray [15] to identify in WT HIV-1 protease the
active-site residues mostly involved in the discrimination of cleavable and non-cleavable
peptides. Following their algorithm, the HIV-1 protease – peptide complexes are repre-
sented in atomic resolution, as opposed to a coarse-grain representation. With respect to
the algorithm described in [15], our algorithm (Figure 4) has a larger number of cycles
(8x4x6=192 compared to 8x12=96), and more ’small’ and ’shear’ moves for the pertur-
bation of both the side chain and the backbone atoms. The side chain conformations are
further optimized through a repacking algorithm [32] and using the extended Dunbrack
library [33, 34]. The moves are applied to all residues of the substrate peptide plus a se-
lected number of residues of the protease, with the following criterion: all residues inside a
5 A˚ distance from any atom of the substrate peptide, plus all the residues reported as ac-
tive by Chaudhury and Gray [15], plus their ±1 neighbours, plus if one residue is included
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on only one chain it is made to be included in both. After the moves, an energy mini-
mization step is performed, based on the Davidon-Fletcher-Powell method [35, 36]. Each
structure is then accepted or rejected based on a Monte Carlo (MC) criterion depending
on the standard RosettaDock energy function [32, 33, 37–39]. Along the optimization a
temperature gradient was applied, from an initial value of kT = 3.0 to 1.0, unless differ-
ently stated. 500 decoy structures were generated using 5 parallel algorithm runs, each
producing 100 structures.
The main difference with the algorithm of [15] is that after the algorithm produced
500 decoy structures, the lowest in energy is chosen and used as a starting structure
for another cycle of optimization. This process is repeated K times, until convergence.
It was found that, after at least 5 cycles, the computed RosettaDock energy did not
change between subsequent cycles as soon as all 5 parallel runs of a single cycle produced
structures with the same energy. Consequently, in order to render as automatic as possible
the algorithm, the fact that K > 5 and that each parallel run produced, as best structure,
a decoy with the same energy was taken as a mark for convergence. It was found that,
on average, a value of K = 20 was sufficient. As an example, Figure 5 reports the energy
of WT-PR bound to TF-PR along the optimization. The points at each step corresponds
to the RosettaDock energy of the lowest in energy decoy out of the 500 computed at that
particular step. Such structure would then be used as starting point for the next cycle. At
the end of the K cycles the lowest in energy decoy is chosen as the PyRosetta optimized
structure.
The same algorithm was also used for the optimization of mutant HIV-1 proteases
(vide infra), the octa-peptides alone, and the protease alone as apo-protein.
The starting structures were prepared from that of HIV-1 protease in complex with an
inhibitor (PDB accession code 1HXB [40]), considered as apo-protein. In order to place
the substrate peptide, the structure of a D25N deactivated protease in complex with the
natural substrate peptide p2-NC (PDB accession code 1KJ7 [9]) was aligned with respect
to the backbone atoms of the protease (RMS = 0.436 A˚). The starting structure was
then composed using the apo-protein from 1HXB and the substrate peptide from 1KJ7.
All subsequent protease-peptide complexes were created starting from this structure and
mutating the peptide accordingly. See Table 1S, Table 3S and Table 4S for a complete list
of the considered substrate peptides. Hydrogen atoms were added through the program
Pymol [41].
Further Structures Optimization and Energetic Re-evaluation
The position of the hydrogen atoms of each PyRosetta generated structure was optimized
using Open Babel [42] with the MMFF94 [43–47] force field. The energy of each structure
was finally re-evaluated at the higher level of theory ‘FMO2-MP2/6-31G(d)/PCM[1]’.
Single point energy evaluations were carried out using the fragment molecular orbital
(FMO) approximation [48, 49], as implemented in GAMESS [50]. Each FMO calculation
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was carried out at the MP2 level of theory [51] with the 6-31G(d) basis set [52, 53] and
the Polarazible Continuum Model (PCM) approximation [54,55]. Pairs of fragments sep-
arated by more than two van der Waals radii were calculated using a Coulomb expression
for the interaction energy and ignoring correlation effects (RESDIM=2.0 RCORSD=2.0
in $FMO). The input files for the FMO calculations were prepared using the program
FRAGIT [56].
Binding Energies Evaluation
The re-evaluated energy of every optimized structure was used to compute the binding
energy of PR with different substrate peptides. The binding energy (EBind) of HIV-1
protease (wild type or mutated) and a peptide was evaluated with equation (1), where
EComplex is the energy of the complex, EAPO the energy of the protease optimized as
apo-protein, EPep the energy of the optimized peptide.
EBind = EComplex − (EAPO + EPep) (1)
These binding energies can not be directly compared to experimental values, for which
a much more complex and accurate methodology is required [57]. These energies were
used only to qualitatively compare different PR – peptide combinations.
Mutation Algorithm
A similar procedure as that described in Figure 4 was used to produce mutant HIV-
1 proteases, possibly capable of cleaving a given peptide different from the endogenous
substrate peptides. The general idea was to ’expose’ the protease to a different peptide
and allow some residues to change in order to accommodate it better. A target octa-
peptide was chosen: HLSF*MAIP, where the * symbol indicates the desired cleaving site.
The peptide sequence was extracted from that of κ-casein.
The assumption behind the algorithm is that lowering the energy of the PR – peptide
complex by changing the side chains of selected residues would decrease also the binding
energy, thus increasing the cleavability.
Two different methodologies were designed to predict mutant PRs, Strategy1 and
Strategy2. The Strategy1 mutation algorithm is depicted in Figure 6. Each optimization
step corresponds to the algorithm of Figure 4. In the mutation steps (also based on
the previous algorithm), the Dunbrack library of rotamers includes all rotamers of all
amino acids, but only for a selected number of residues. The six specificity determining
residues, as found by [15], are chosen to be altered. In other words, during the mutation
step, whenever one of the alterable residues is being optimized, the random choice of
a test rotamer is among all possible amino acids. In Scheme A alterations are allowed
on all 6 residues on both chains, for a total of 12 alterable residues. Thus, side-chain
perturbation and repacking rotamer choice is performed randomly selecting among 12 x
12
20 = 240 possible amino acids. In Scheme B only alterations on L76 and V82 of Chain
A and D30, I47, G48, and I84 of Chain B are allowed, for a total of 6 alterable residues.
In this case, side-chain perturbation and repacking rotamer choice is performed with a
random selection among 6 x 20 = 120 possible amino acids. Each mutation step took
ca. 40 hours on 5 cpus to produce 500 decoys. The lowest energy decoy is then chosen
as starting structure for the next step. The energy of the structure is evaluated with the
standard RosettaDock energy function. The residue reference energy part of the energy
function [32] takes into account also the differences between different amino acids. In other
words, energy differences between two mutant structures originates solely from different
side chain interactions rather than from a different number of atoms.
Both the mutation and the optimization steps were repeated K ′ and K times, respec-
tively. The mutation cycles are considered converged once two following cycles do not
introduce new mutations. Different values of K and K ′ were found necessary to reach
convergence. After a series of mutation cycles (K ′ ≥ 8), a series of optimization cycles
was performed (K ≥ 8), followed by another usually shorter mutation cycle (K ′ ≤ 3) and
finally a short optimization cycle (K ≤ 3).
Among the naturally cleaved peptides, TF-PR (sequence SFNF*PQIT) was chosen as
a starting substrate peptide, since it is the most similar, in terms of conserved residues,
to the target peptide (sequence HLSF*MAIP). Consequently, the optimized structure of
WT protease in complex with the TF-PR peptide was chosen as starting template. The
substrate peptide sequence was altered one amino acid at the time, as reported in Ta-
ble 10S. After each peptide alteration, a series of protease mutation and optimization
cycles were performed. Once convergence was reached, a new peptide single amino acid
change was introduced and the procedure repeated. Different mutant PRs were obtained
from different runs by changing a few parameters, e.g. the initial temperature of the simu-
lation. These parameters are specified in Table 7S. Some mutant PRs were also produced
by ’exposing’ the protease directly to the target peptide without prior intermediates (mu-
tation Scheme F). This last process required a higher number of K ′ cycles (K ′ ≥ 15), but
without having to cycle through one substrate peptide residue at the time.
All mutant PRs obtained through Strategy1 were heterodimers. By simply equalizing
alterations on both chains a number of extra homodimer mutant PRs were also obtained.
These structures were subsequently optimized as previously described.
In Strategy2 the number of residues allowed to change was increased in order to include
all amino acids residing inside a 3 A˚ radius from the TF-PR peptide. In other words,
we chose those residues with at least one atom that is distant at most 3 A˚ from any
atom of the substrate peptide. The specificity determining residues were also included
in the set of alterable amino acids, if not already present. The residues Asp25, Thr26
and Gly27 of both chains were excluded from the set, since they represent the catalytic
triad [5]. The full set of 26 residues is reported in Table 9S. Thus, side-chain perturbation
and repacking rotamer choice is performed randomly selecting among 26 x 20 = 520
possible amino acids. The mutant PRs were generated using the target peptide directly
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(Scheme F). Each mutation step took a bit more than 3 days on 5 cpus to produce 500
decoy structures. An initial temperature of 9 kT was usued. K ′ = 6 mutation cycles
were performed. The lowest in energy decoy after each mutation step was subsequently
optimized (two after the first step). The sixth mutation step did not introduce any new
mutation in PR and the mutation cycle was stopped.
Also the mutant PRs obtained through Strategy2 were heterodimers. Only the ho-
modimer of the final mutant PR was considered, see Table 5.
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Figure 1. ROC plot comparing different cutoff values for binding energies
computed through FMO energy re-evaluation or RosettaDock energy
function. The values for each method closest to the theoretical optimum (0,1) are
highlighted. The computed area under the ROC curve is 0.79 and 0.80 for FMO and
Rosetta, respectively. The raw data is reported in Table 11S.
Figure 2. Backbone difference between PyRosetta computed structures of
WT-PR and M24. The optimized structures of WT-PR and M24 binding the target
peptide were aligned with respect to their α-carbon atoms using PyMol. The backbone
of M24 (red) is almost coincident with that of WT-PR (green) with a RMS of 0.227 A˚.
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Figure 3. Spatial disposition of the residues changed by Strategy2. The six
residues of chain A (top) and 6 residues of chain B (bottom) are highlighted in
ball-and-sticks. The reported structure (as semi-transparent cartoon) is that of WT-PR
optimized when binding the target peptide (only the backbone is shown in sticks).
Figures 3S - 14S report the full residue by residue changes. A movie showing the three
dimensional structure is included as Supporting Material.
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Figure 4. PyRosetta based optimization algorithm. φ, ψ, χ represent
perturbations applied to both backbone and side chain dihedral angles. MC criterion
stands for a Monte Carlo based check of decoy structures.
Figure 5. Optimization algorithm convergence. Example of energy convergence
during the various macro cycles of the optimization algorithm for WT-PR in complex
with TF-PR peptide. Each point along the graph corresponds to the energy (computed
with the RosettaDock energy function) of the lowest in energy decoy out of 500
produced during each of the K steps.
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Figure 6. PyRosetta based mutation algorithm. The optimization step is the
algorithm presented in Figure 4. In the mutation step the side chain perturbation for the
six specificity determining residues is among all possible rotamer of all 20 amino acids.
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Tables
Table 1. Computed binding energies of WT-PR and cleavable endogenous
peptides.
Substrate Peptide FMO (kcal/mol) RosettaDock (kT) exp Km (mM) [22]
MA-CA -57 -9 0.15
CA-p2 -52 -6 0.01
p2-NC -72 -4 0.05
NC-p1 -68 -3
p1-p6 -47 1
p6pol-PR -41 -6
TF-PR -62 -5 <0.01
PR-RTp51 -64 -7 0.07
RTp51-RTp66 -68 -12 0.04
RTp66-INT -62 -6
RH-IN -63 -10 0.006
24
Table 2. Comparison of WT-PR computed binding energies.
RosettaDock
Energy Function
FMO Energy
Re-evaluation
Average endogenousa -6 (kT) -60 (kcal/mol)
(Standard deviation) (3) (kT) (10) (kcal/mol)
Average all cleavableb -5 (kT) -43 (kcal/mol)
(Standard deviation) (3) (kT) (22) (kcal/mol)
Average non cleavablec -1 (kT) -15 (kcal/mol)
(Standard deviation) (4) (kT) (28) (kcal/mol)
U test probability
(all cleavable VS non-cleavable)
1.46 · 10−7 2.21 · 10−7
U test probability
(only endogenous VS non-cleavable)
3.49 · 10−4 6.16 · 10−6
a Table 1.
b Table 1 plus Table 5S.
c Table 6S.
Energies were computed with the standard RosettaDock energy function, as described
in [15] and with the FMO re-evaluation. A Mann-Whitney’s U test probability was
evaluated by comparing the binding energies of the set of endogenous peptide against
the non-cleavable and the entire set of cleavable peptides against the non-cleavable. The
FMO based binding energies are more clear in discriminating cleavable and non
cleavable peptides than the Rosetta based ones.
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Table 3. FMO computed binding energies of HIV-1 protease WT and Pr3
set of mutant PRs.
PR Peptides
RTp51-RTp66 poly-Ala poly-Arg TF-PR CA-p2 p2-NC
WT-PR -68 -15 -41 -62 -52 -72
Single mutant
A28S -65 -12 -35 -41 -13 -67
D30F -48 -1 0 -7 -4 -43
G48R -66 -44 -27 -55 -15 -43
Double mutant
A28SD30F -44 -16 30 -35 -22 -55
A28SG48R -96 -16 -54 -35 -14 -60
D30FG48R -76 3 18 -19 -1 -54
Triple mutant
A28SD30FG48R -42 -21 12 -32 -12 -63
Computed binding energies (kcal/mol) of WT and mutant HIV-1 proteases in complex
with RTp51-RTp66, poly-alanine, poly-arginine, TF-PR, CA-p2 and p2-NC peptides.
Table 4. FMO computed binding energies of HIV-1 protease WT and
selected drug resistance mutant PRs (DR set).
PR Peptides
NC-p1WT NC-p1K436R NC-p1A431V poly-Ala poly-Arg
WT-PR -49 -70 -56 -15 -41
D30N -29 -44 -36 -15 -23
I50L -64 -49 -54 -16 -49
I50V -54 -46 -52 -18 -34
V82A -45 -54 -52 -16 -38
I84V -46 -75 -35 -23 -38
I84V L90M -55 -67 -55 -20 -46
Computed binding energies (kcal/mol) of WT-PR and selected drug resistance mutant
proteases in complex with NC-p1 as wild type, K436R and A431V drug resistance
associated mutant peptides, poly-alanine and poly-arginine peptides.
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Table 5. Strategy2 suggested mutant PRs.
Mutant ID Chain A Chain B Mutation
Scheme
Notes
M17 A28S D30T A28S D30T
K45M I50L V82F
F After one mutation step
M18 A28S D30T I50L
P81D V82R I84V
A28S D30T
K45M I50L V82Y
F After one mutation step
M19 A28S D30T I50L
P81D V82R I84V
A28S D30T K45A
I50L V82Y I84L
F After two mutation steps
M20 A28S D30T I50L
P81D V82R I84V
A28S D30T K45D
I50L V82Y I84L
F After three mutation steps
M21 A28S D30T I50L
P81L V82Y I84V
A28S D30T K45D
I50L V82Y
F After four mutation steps
M22 A28S D30T I50L
P81L V82Y
A28S D30T K45A
I50L V82Y
F After five mutation steps
M23 A28S D30T I50L
P81L V82Y
A28S D30T K45A
I50L V82Y
F After six mutation steps
M24 A28S D30T K45A
I50L P81L V82Y
A28S D30T K45A
I50L P81L V82Y
– Homodimer of M22
M17 – M23 represent the subsequent generations of mutant PRs suggested by
Strategy2. All mutant enzymes were generated following Scheme F.
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Table 6. FMO computed binding energies of HIV-1 protease WT and
Strategy2 mutant PRs.
PR Peptides
Target poly-Ala poly-Arg TF-PR CA-p2 p2-NC
WT-PR -9 -15 -41 -62 -52 -72
Gen 1
M17 -34 -13 -47 -68 -82 -74
M18 -24 -19 -45 -82 -62 -63
Gen 2
M19 -17 2 1 -67 -46 -81
Gen 3
M20 -23 -2 -19 -67 -33 -84
Gen 4
M21 -20 2 7 -37 -32 -18
Gen 5
M22 -29 -6 10 -42 -25 -30
M24 -29 -11 7 -44 -33 -33
Computed binding energies (kcal/mol) of WT-PR and Strategy2 mutant proteases in
complex with Target, poly-alanine, poly-arginine, TF-PR, CA-p2 and p2-NC peptides.
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In silico prediction of mutant HIV-1 pro-
teases cleaving a target sequence
Jan H. Jensen, Martin Willemoe¨s, Jakob R. Winther, Luca De Vico
The video animation of the optimized structure of WT-PR binding the target peptide
with highlighted residues can be found at this link: http://youtu.be/NEXKojTw2Bc .
Table 1S. Cleavable peptides.
P4 P3 P2 P1 * P1’ P2’ P3’ P4’
MA-CA S Q N Y * P I V Q
CA-p2 A R V L * A E A M
p2-NC A T I M * M Q R G
NC-p1 R Q A N * F L G K
p1-p6 P G N F * L Q S R
p6pol-PR S F N F * P Q V T
TF-PR S F N F * P Q I T
PR-RTp51 T L N F * P I S P
RTp51-RTp66 A E T F * Y V D G
RTp66-INT R K V L * F L D G
RH-IN R K I L * F L D G
List of the cleavable endogenous peptides considered in this work
S-2
Table 2S. Extra cleavable peptides.
P4 P3 P2 P1 * P1’ P2’ P3’ P4’
K001 T Q I M * F E T F
K002 G Q V N * Y E E F
K003 P F I F * E E E P
K005 D T V L * E E M S
K007 A E E L * A E I F
K008 S L N L * R E T Q
K010 A E C F * R I F D
K011 D Q I L * I E I C
K012 D D L F * F E A D
K013 Y E E F * V Q M M
K014 P I V G * A E T F
K016 R E A F * R V F D
K018 A Q T F * Y V N L
K019 P T L L * T E A P
K020 S F I G * M E F K
K021 D A I N * T E F K
K022 Q I T L * W Q R P
K023 E L E F * P E G G
K029 K E L Y * P L T S
K031 S R S L * Y A S S
K032 A E A M * S Q V T
K034 G S H L * V E A L
K035 G G V Y * A T R S
K036 F R S G * V E T T
K037 V E V A * E E E E
K038 L P V N * G E F S
K039 E T T A * L V C D
K040 H L V E * A L Y L
K041 H Y G F * P T Y G
K042 D S A D * A E E D
K043 G W I L * G E H G
K045 Q A I Y * L A L Q
K046 E K V Y * L A W V
K047 V E I C * T E M E
K048 T Q D F * W E V Q
K049 L W M G * Y E L H
K050 G D A Y * F S V P
K051 E L E L * A E N R
K052 S K D L * I A E I
K053 L E V N * I V T D
K054 I I V A * C E G N
K056 G G N Y * P V Q H
K057 A R L M * A E A L
K058 P F A A * A Q Q R
K059 P R N F * P V A Q
K060 G L A A * P Q F S
K061 S L N L * P V A K
K063 R Q V L * F L E K
K064 Q M I F * E E H G
SUB3 Q I T L * W K R P
T035 V E I C * T E M E
T084 T Q D F * W E V Q
T112 G D A Y * F S V P
T228 L W M G * Y E L H
T300 E L E L * A E N R
T322 S K D L * I A E I
T480 Q A I Y * L A L Q
T491 L E V N * I V T D
T529 E K V Y * L A W V
List of the cleavable non-endogenous peptides considered in this work
S-3
Table 3S. Other peptides
P4 P3 P2 P1 * P1’ P2’ P3’ P4’
Target H L S F * M A I P
NC-p1A431V R Q V N * F L G K
NC-p1K436R R Q A N * F L G R
poli-Ala A A A A * A A A A
poli-Arg R R R R * R R R R
List of other peptides considered in this work
S-4
Table 4S. Non-cleavable peptides
P4 P3 P2 P1 * P1’ P2’ P3’ P4’
NBP1 V N C A * K K I V
NBP2 W R N R * C K G T
NBP3 M M K S * R N L T
NBP4 L A A A * M K R H
NBP5 T T Q A * N K H I
T015 G M D G * P K V K
T031 I K A L * V E I C
T033 A L V E * I C T E
T037 I C T E * M E K E
T039 T E M E * K E G K
T080 L N K R * T Q D F
T082 K R T Q * D F W E
T086 D F W E * V Q L G
T088 W E V Q * L G I P
T108 V L D V * G D A Y
T110 D V G D * A Y F S
T114 A Y F S * V P L D
T116 F S V P * L D E D
T224 E P P F * L W M G
T226 P F L W * M G Y E
T230 M G Y E * L H P D
T232 Y E L H * P D K W
T296 T E E A * E L E L
T298 E A E L * E L A E
T302 E L A E * N R E I
T304 A E N R * E I L K
T318 Y Y D P * S K D L
T320 D P S K * D L I A
T324 D L I A * E I Q K
T326 I A E I * Q K Q G
T441 Y V D G * A A N R
T476 K T E L * Q A I Y
T478 E L Q A * I Y L A
T482 I Y L A * L Q D S
T484 L A L Q * D S G L
T487 Q D S G * L E V N
T489 S G L E * V N I V
T493 V N I V * T D S Q
T495 I V T D * S Q Y A
T525 L I K K * E K L A
T527 K K E K * V Y L A
T531 V Y L A * W V P A
T533 L A W V * P A H K
List of non-cleavable peptides considered in this work
S-5
Table 5S. Computed binding energies of WT-PR and non-endogenous
cleavable peptides.
Substrate
Peptide
FMO
(kcal/mol)
RosettaDock
(kT)
Substrate
Peptide
FMO
(kcal/mol)
RosettaDock
(kT)
K001 -22 -2 K043 -67 -5
K002 -33 -4 K045 -55 -5
K003 -16 -8 K046 -39 -4
K005 -24 -4 K047 -79 -5
K007 -27 -1 K048 -86 -9
K008 -40 -2 K049 -40 -5
K010 -55 -4 K050 -36 -7
K011 -42 -3 K051 -31 -2
K012 -22 -7 K052 -4 1
K013 -36 -2 K053 -51 -4
K014 -29 -3 K054 -56 -1
K016 -73 -3 K056 -70 -5
K018 -72 -4 K057 -7 -6
K019 -61 -9 K058 -35 -2
K020 -8 -3 K059 -58 -6
K021 -64 -8 K060 -36 -5
K022 -45 -5 K061 -34 -5
K023 -63 -11 K063 -61 -3
K029 -48 -4 K064 -2 -7
K031 -32 -5 SUB3 -30 -6
K032 -51 -6 T035 -67 -4
K034 -8 -8 T084 -81 -7
K035 -30 -8 T112 -69 -11
K036 -3 -3 T228 -29 -5
K037 -2 -4 T300 -29 -1
K038 -39 -5 T322 -21 1
K039 -10 0 T480 -62 -5
K040 -30 -6 T491 -56 -1
K041 -53 -6 T529 -27 1
K042 -29 -6
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Table 6S. Computed binding energies of WT-PR and non-cleavable peptides.
Substrate
Peptide
FMO
(kcal/mol)
RosettaDock
(kT)
Substrate
Peptide
FMO
(kcal/mol)
RosettaDock
(kT)
NBP1 -18 3 T296 43 2
NBP2 -21 3 T298 -54 -2
NBP3 -63 0 T302 -44 4
NBP4 -18 4 T304 1 -2
NBP5 -68 7 T318 23 0
T015 2 -3 T320 23 -2
T031 -29 -6 T324 -18 0
T033 -10 -2 T326 -10 5
T037 -28 -5 T441 -30 -2
T039 -36 -3 T476 -10 1
T080 -45 4 T478 -33 -2
T082 9 -2 T482 -45 -1
T086 -23 0 T484 -24 -2
T088 -42 3 T487 31 -3
T108 -12 -4 T489 -24 -6
T110 -21 -3 T493 -19 -1
T114 -16 -8 T495 -15 1
T116 -10 -2 T525 61 7
T224 48 -1 T527 -9 1
T226 -49 -9 T531 -5 -5
T230 19 -2 T533 -23 -7
T232 -13 -1
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Table 7S. Strategy1 suggested mutant PRs.
Mutant ID Chain A Chain B Mutation
Scheme
Notes
M1 V82R I84V D30Y V82I A
M2 V82Y D30V B
M3 D30T D30V V82I B F
M4 D30Y V82R D30Y V82R – Homodimer of M1
M5 D30V V82Y D30V V82Y – Homodimer of M2
M6 D30V D30V – Homodimer of M3
M7 D30T I84V D30V V82F A F Initial temperature = 9 kT
M8 D30V B F Initial temperature = 9 kT
M9 D30T I47L L76F
V82R I84T
D30E V82Y A Initial temperature = 6 kT
M10 V82Y D30T I84L B Initial temperature = 6 kT
M11 D30V V82Y I84V D30H I47L L76F
V82Y
A Initial temperature = 12 kT
M12 V82Y D30T B Initial temperature = 12 kT
M13 D30E L76F V82R D30E L76F V82R – Homodimer of M9
M14 D30T V82Y I84L D30T V82Y I84L – Homodimer of M10
M15 D30H I47L V82Y D30H I47L V82Y – Homodimer of M11
M16 D30T V82Y D30T V82Y – Homodimer of M12
Different mutant PRs were obtained by small modifications of the mutation algorithm.
Inside Strategy1 two different schemes were used when choosing which residues could
mutate. In Scheme A all six specificity determining residues were allowed to mutate on
both chains. In Scheme B only residues 76 and 82 were set as mutable on Chain A and
30, 47, 48, and 84 on Chain B. In addition, a straight forward variant of the algorithm
was tested, as opposed to the step-wise one presented in Table 10S. In this variant
(Scheme F) the protease was directly ’exposed’ to the final target peptide sequence. A
K value in the order of 20 was necessary. Other parameters that differ from those
specified in the Computational Methods section are also highlighted.
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Table 8S. FMO computed binding energies of HIV-1 protease WT and
Strategy1 mutant PRs.
PR Peptides
Target poly-Ala poly-Arg TF-PR CA-p2 p2-NC
WT-PR -9 -15 -41 -62 -52 -72
M1 -7 3 28 -41
M2 -13 -9 12 -41
M3 -8 -4 13 -43
M4 -18 -24 17 -52
M5 -30 -14 4 -54 -27 -73
M6 -14 2 -1 -14
M7 -7 -2 3 -49
M8 -10 -9 -5 -55
M9 20 17 14 -36
M10 40 11 -3 -43
M11 5 10 45 -44
M12 2 2 16 -43
M13 3 2 -24 -52
M14 3 8 17 -60
M15 -9 2 71 -51
M16 -8 -6 26 -44
Computed binding energies (kcal/mol) of WT-PR and Strategy1 mutant proteases in
complex with target, poly-alanine, poly-arginine, TF-PR, CA-p2 and p2-NC peptides.
S-9
Table 9S. Residues set as mutable in Strategy 2.
Chain A Chain B
Arg 8 Arg 8
Ala 28 Leu 23
Asp 29 Ala 28
Asp 30 Asp 29
Val 32 Asp 30
Gly 48 Lys 45
Gly 49 Ile 47
Ile 50 Gly 48
Leu 76 Gly 49
Thr 80 Ile 50
Pro 81 Pro 81
Val 82 Val 82
Ile 84 Ile 84
The residues were selected as those inside a 3 A˚ radius from the substrate peptide plus
the specificity determining residues, if not included, minus the catalytic triad Asp25,
Thr26 and Gly27 on both chains. The optimized structure of WT protease in complex
with the TF-PR peptide was used as template.
Table 10S. Substrate peptide mutation sequence
P4 P3 P2 P1 * P1’ P2’ P3’ P4’
Start Ser Phe Asn Phe * Pro Gln Ile Thr
His Phe Asn Phe * Pro Gln Ile Thr
His Phe Asn Phe * Pro Gln Ile Pro
His Leu Asn Phe * Pro Gln Ile Pro
His Leu Asn Phe * Pro Ala Ile Pro
His Leu Ser Phe * Pro Ala Ile Pro
Target His Leu Ser Phe * Met Ala Ile Pro
Step wise sequence of substrate peptides employed in the mutation algorithm. The
starting sequence corresponds to the natural substrate TF-PR. This sequence is altered
one amino acid at the time towards that of the desired target sequence. The P1 and P3’
position were not changed during the sequence.
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Table 11S. ROC data.
Total
FMO Rosetta
cutoff True
positive
False
positive
Distance
to (0, 1)
cutoff True
positive
False
positive
Distance
to (0, 1)
-inf 1.00 1.00 1.00 -inf 1.00 1.00 1.00
-10 0.90 0.67 0.68 4 1.00 0.88 0.88
-15 0.89 0.56 0.57 3 1.00 0.84 0.84
-20 0.87 0.44 0.46 2 1.00 0.77 0.77
-25 0.81 0.30 0.35 1 0.99 0.74 0.74
-30 0.71 0.26 0.38 0 0.94 0.63 0.63
-35 0.61 0.21 0.44 -1 0.93 0.58 0.59
-40 0.53 0.19 0.51 -2 0.84 0.37 0.40
-45 0.47 0.09 0.54 -3 0.74 0.23 0.35
-50 0.44 0.07 0.56 -4 0.61 0.19 0.43
-55 0.39 0.05 0.62 -5 0.50 0.14 0.52
-60 0.30 0.05 0.70 -6 0.27 0.09 0.73
-65 0.17 0.02 0.83 -7 0.20 0.05 0.80
-70 0.09 0.00 0.91 -8 0.13 0.05 0.87
-75 0.04 0.00 0.96 -9 0.06 0.00 0.94
-80 0.03 0.00 0.97 -10 0.04 0.00 0.96
-85 0.01 0.00 0.99 -11 0.01 0.00 0.99
+inf 0.00 0.00 1.00 +inf 0.00 0.00 1.00
Only endogenous
FMO Rosetta
cutoff True
positive
False
positive
Distance
to (0, 1)
cutoff True
positive
False
positive
Distance
to (0, 1)
-inf 1.00 1.00 1.00 -inf 1.00 1.00 1.00
-10 1.00 0.67 0.67 4 1.00 0.88 0.88
-15 1.00 0.56 0.56 3 1.00 0.84 0.84
-20 1.00 0.44 0.44 2 1.00 0.77 0.77
-25 1.00 0.30 0.30 1 0.91 0.74 0.75
-30 1.00 0.26 0.26 0 0.91 0.63 0.63
-35 1.00 0.21 0.21 -1 0.91 0.58 0.59
-40 1.00 0.19 0.19 -2 0.91 0.37 0.38
-45 0.91 0.09 0.13 -3 0.91 0.23 0.25
-50 0.82 0.07 0.19 -4 0.73 0.19 0.33
-55 0.73 0.05 0.28 -5 0.73 0.14 0.31
-60 0.64 0.05 0.37 -6 0.36 0.09 0.64
-65 0.27 0.02 0.73 -7 0.36 0.05 0.64
-70 0.09 0.00 0.91 -8 0.27 0.05 0.73
-75 0.00 0.00 1.00 -9 0.18 0.00 0.82
-80 0.00 0.00 1.00 -10 0.09 0.00 0.91
-85 0.00 0.00 1.00 -11 0.09 0.00 0.91
+inf 0.00 0.00 1.00 +inf 0.00 0.00 1.00
Comparison of ROC data for FMO energy re-evaluation and RosettaDock energy
function generated binding energies, while considering different cutoff values. The upper
part of the table reports the full comparison between known cleavable and non cleavable
peptides. In the lower part, data for only the endogenous peptides was used for the
cleavable part. True positive data is reported in the graphs as sensitivity, false positive
as 1 - specificity. Theoretical values for ± infinite cutoff have been added.
S-11
-15
-10
-5
0
5
10
-100 -80 -60 -40 -20 0 20 40 60 80
R
os
et
ta
D
oc
k 
bi
nd
in
g 
En
er
gi
es
 (k
T)
FMO binding energies (Kcal/mol)
R2 = 0.15435
Figure 1S. Correlation plot between FMO and RosettaDock computed
binding energies. The linear trend line shows no correlation between the data (R2 =
0.15435).
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Figure 2S. ROC plot comparing different cutoff values for binding energies
computed through FMO energy re-evaluation or RosettaDock energy
function. The values for each method closest to the theoretical optimum (0,1) are
highlighted. The comparison was done using the data of only the endogenous peptides
for the cleavable peptides part. The computed area under the ROC curve is 0.96 and
0.84 for FMO and Rosetta, respectively. The raw data is reported in Table 11S.
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Figures 3S - 14S compare the changes between WT-PR andM24 , residue by residue.
In each figure the enzyme is represented as semi-transparent ribbon, the peptide as sticks
and the changing residue as ball-and-sticks. The peptide residues numbering is from 2 to
9. Each residue changed by Strategy2 is indicated by a label containing the chain, the
residue name and its number.
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A28S
WT
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Figure 3S. Chain A, residue 28.
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D30T
WT
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Figure 4S. Chain A, residue 30.
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K45A
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Figure 5S. Chain A, residue 45.
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Figure 6S. Chain A, residue 50.
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Figure 7S. Chain A, residue 81.
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Figure 8S. Chain A, residue 82.
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Figure 9S. Chain B, residue 28.
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Figure 10S. Chain B, residue 30.
S-21
K45A
WT
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Figure 11S. Chain B, residue 45.
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WT
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Figure 12S. Chain B, residue 50.
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WT
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Figure 13S. Chain B, residue 81.
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V82Y
WT
M24
Figure 14S. Chain B, residue 82.
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